Douglas Cunningham, DO
Family Medicine · Phoenix, AZNPI 1104856475
Payments from drug & device makers
Across 3,469 payments — averaging $1414.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$2.4M
- Viiv Healthcare Company$1.3M
- Gilead$592K
- Janssen Products, LP$329K
- EMD Serono, Inc.$66K
- GSK$52K
- plus $103K from 32 others
Across 19 payments — averaging $146.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$2K
- Gilead$944
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 518 | $2,423,415 |
| Viiv Healthcare Company | 1,178 | $1,340,170 |
| Gilead | 891 | $592,347 |
| Janssen Products, LP | 365 | $329,103 |
| EMD Serono, Inc. | 114 | $66,171 |
| GSK | 19 | $52,236 |
| Janssen Research & Development, LLC | 13 | $49,309 |
| Janssen Scientific Affairs, LLC | 38 | $15,128 |
| Theratechnologies Inc. | 44 | $12,106 |
| Napo Pharmaceuticals Inc | 27 | $8,282 |
| Pfizer | 3 | $8,175 |
| Lilly USA, LLC | 16 | $6,002 |
| Johnson & Johnson(2 entities) | 122 | $2,089 |
| AbbVie | 45 | $804 |
| Abbott | 11 | $233 |
| Novo Nordisk | 11 | $214 |
| AstraZeneca | 12 | $171 |
| Boehringer Ingelheim | 6 | $126 |
| Lucid Diagnostics Inc. | 3 | $116 |
| Teva Pharmaceuticals USA, Inc. | 6 | $103 |
| Astellas Pharma US Inc | 3 | $94 |
| Amgen | 4 | $76 |
| Medtronic | 3 | $41 |
| Sanofi-aventis U.S. LLC | 2 | $32 |
| Biohaven Pharmaceuticals, Inc. | 2 | $27 |
| Sanofi Pasteur Inc. | 1 | $25 |
| Hologic Sales And Service, LLC | 1 | $24 |
| Aimmune Therapeutics, Inc. | 1 | $22 |
| Novartis | 1 | $21 |
| Tolmar, Inc. | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Eisai Inc. | 1 | $18 |
| Dexcom, Inc. | 1 | $18 |
| Seqirus USA Inc | 1 | $17 |
| Intra-sana Laboratories | 1 | $13 |
| Acerus Pharmaceuticals Corporation | 1 | $12 |
| Amarin Pharma, Inc. | 1 | $12 |
| Dynavax Technologies Corporation | 1 | $10 |
How this compares
$4,906,802 in reported general payments places this provider in the 95th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other family medicine in Phoenix
- Brock MerrittPhoenix$8.4M
- Jeffrey ZacherPhoenix$2M
- Trisha TavaresPhoenix$1.6M
- David FrancykPhoenix$1.3M
- James BeachPhoenix$1.2M
- Peter LevinsPhoenix$971K
- Elysa ShawPhoenix$774K
- Mitchell EdelsteinPhoenix$741K
- Brian DedinskyPhoenix$589K
- Sylvia GutierrezPhoenix$356K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.